Core Insights - Pangea Natural Foods Inc. announces a strategic collaboration with Dr. Neal Davies and Dr. Raimar Loebenberg to enhance non-injectable peptide delivery systems for consumer wellness applications [1][5] Group 1: Collaboration Details - Amino Innovations, a subsidiary of Pangea, will leverage the expertise of two renowned pharmaceutical scientists to accelerate research and development [1][2] - The collaboration will utilize the University of Alberta's Drug Development and Innovation Centre for formulation and validation [2] Group 2: Research Scope - The partnership aims to establish benchmarks for precision peptide delivery across various formulations, including oral, dermal, and topical [3] - Research will focus on the absorption, bioavailability, and stability of peptides like BPC-157, GHK-Cu, and KPV, using natural enhancers [3][4] Group 3: Strategic Goals - The data generated will enhance Amino Innovations' intellectual property portfolio and regulatory credibility, facilitating new product development in nutraceutical and cosmeceutical markets [4] - The collaboration is expected to create scientific transparency in the wellness industry by generating pharmacokinetic and permeability data [5][6]

Core Points - Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals for health and beauty [1][6] - The company will present at the Skyline Signature Series™ on October 8, 2025, at 11:00 AM ET, allowing investors to engage in real-time Q&A [1][2][3] Event Details - Event Name: Skyline Signature Series™ [3] - Date: October 8, 2025 [3] - Time: 11:00 AM ET [3] - Registration Link: https://us02web.zoom.us/webinar/register/WN_wWWf2nr8QZmKgzx7IaKrXA/registration [3] About Skyline Corporate Communications Group - Skyline Corporate Communications Group, LLC provides investor relations services and ensures a high-quality audience for public companies through careful vetting [4][5] - The firm has experience in strategic messaging and investor communications for public corporations across various industries [5]

Core Viewpoint - COSCIENS Biopharma Inc. has appointed Anna Biehn as the new Chief Executive Officer, effective May 5, 2025, succeeding Gilles Gagnon, who will remain as a Strategic Advisor and Director [1][3]. Company Overview - COSCIENS Biopharma Inc. is a life science company that develops and commercializes a diversified portfolio of cosmeceutical, nutraceutical, and pharmaceutical products [5][6]. - The company focuses on leveraging proprietary extraction technology to produce active ingredients from renewable plant resources [5]. Leadership Transition - Anna Biehn brings over 25 years of experience in global general management and marketing, previously serving as Chief Financial Officer at NuTek Natural Ingredients [2][3]. - Gilles Gagnon has been with the company since 2008 and has played a key role in its growth and positioning [3]. Strategic Vision - The company aims to establish itself as a global leader in natural-based products for health and wellness, capitalizing on the growing demand for natural ingredients [3][4]. - Biehn expressed confidence in COSCIENS' portfolio and technology, highlighting significant innovation opportunities for both near-term and long-term value [3]. Market Position - COSCIENS is listed on both the Nasdaq Capital Market and the Toronto Stock Exchange under the ticker symbol "CSCI" [6].